|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Current Assets | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Inventories | |||||||||||||||||||
| Deferred clinical supply costs | |||||||||||||||||||
| License fee and expense reimbursements receivable | |||||||||||||||||||
| Deposit to be refunded | |||||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||||
| Total Current Assets | |||||||||||||||||||
| Intangible assets | |||||||||||||||||||
| Prepaid expenses, non-current | |||||||||||||||||||
| Digital assets | |||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||
| Security deposit | |||||||||||||||||||
| Deferred offering costs | |||||||||||||||||||
| Security deposits, non-current | |||||||||||||||||||
| Digital assets receivable, net | |||||||||||||||||||
| Digital intangible assets | |||||||||||||||||||
| Digital intangible assets receivable, net | |||||||||||||||||||
| Operating lease right-of-use asset | |||||||||||||||||||
| Equipment deposits | |||||||||||||||||||
| Other assets | |||||||||||||||||||
| Total Assets | |||||||||||||||||||
| Liabilities and Stockholders' Equity | |||||||||||||||||||
| Current Liabilities: | |||||||||||||||||||
| Accounts payable | |||||||||||||||||||
| Accrued compensation | |||||||||||||||||||
| Accrued inducement grant | |||||||||||||||||||
| Accrued former licensor obligations | |||||||||||||||||||
| Accrued expenses and other current liabilities | |||||||||||||||||||
| Operating lease liabilities - current portion | |||||||||||||||||||
| Notes payable - current portion, net | |||||||||||||||||||
| Convertible notes payable - net of debt discount of $0 and $263,930 as of December 31, 2025 and December 31, 2024, respectively | |||||||||||||||||||
| Total Current Liabilities | |||||||||||||||||||
| Accrued expenses and other non-current liabilities | |||||||||||||||||||
| Notes payable - non-current portion, net | |||||||||||||||||||
| Convertible notes payable - non-current portion, net of debt discount of $0 and $398,569 as of December 31, 2024 and 2023, respectively | |||||||||||||||||||
| Operating lease liabilities, non-current portion | |||||||||||||||||||
| Total Liabilities | |||||||||||||||||||
| Stockholders' Equity | |||||||||||||||||||
| Preferred stock, $0.0001 par value, 60,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock, 5,435,898 shares designated; 5,235,897 and 5,435,897 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively with a liquidation preference of $50,740,000 as of June 30, 2026 | |||||||||||||||||||
| Common stock, $0.0001 par value, 600,000,000 shares authorized; 7,162,659 and 1,506,369 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | |||||||||||||||||||
| Common stock, $0.0001 par value, 600,000,000 shares authorized; 15,299,832 shares issued and outstanding as of June 30, 2026; 8,762,329 shares issued and 8,680,005 shares outstanding as of December 31, 2025, respectively | |||||||||||||||||||
| Additional paid-in-capital | |||||||||||||||||||
| Treasury stock, at cost, 0 and 82,324 shares as of June 30, 2026 and December 31, 2025, respectively | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total Stockholders' Equity | |||||||||||||||||||
| Total Liabilities and Stockholders' Equity | |||||||||||||||||||
Loading...
